The markets are expected to open marginally lower today as trendsin GIFT Nifty indicate a negative start - ARETE Securities Ltd
The markets are expected to open marginally lower today as trendsin GIFT Nifty indicate a negative start for the broader index afterNifty closed 221 points lower at 24,750 on Thursday.
Adani Enterprises:
The company successfully completed a QIP of equity shares aggregating Rs.4,200crores (USD 500 million), with 1.42 crore shares allocated at Rs.2,962 each.
Axis Bank:
The company reported Q2 FY25 net profit growth of 18% YoY to Rs.6,918crore, with Net Interest Income rising by 10% YoY to Rs.13,483 crore.
Bharti Airtel:
The company acquired 26% equity shares in AMP Energy C&I Thirty PrivateLimited, formed for owning and operating a captive power plant.
Havells India:
The company posted strong Q2 FY25 results with a 16% YoY revenueincrease to Rs.4,533 crore and a 9.5% YoY net profit growth to Rs.273 crore.
Infosys Ltd:
The company saw a share price increase of 2.84% after strong Q2 FY25results, with revenues up by 5.1% YoY to Rs.40,986 crore and net profit risingby 4.8% YoY to Rs.6,516 crore.
Insolation Energy Ltd:
The company achieved over 150% YoY volume growth, with plans to expandsolar module capacity to 4GW and establish 1.5GW cell manufacturing byFY25.
JSW Energy:
The company signed a PPA with GUVNL for a 192 MW wind-solar hybridproject, targeting 20 GW generation capacity and 40 GWh energy storageby 2030.
Mphasis:
The company infused additional equity into its wholly owned subsidiaryMphasis Europe BV, with the transaction executed on an arms-length basis.
Sky Gold:
The company issued 9,99,259 equity shares through QIP at Rs.2,702 pershare, raising Rs.2,700 crores.
Sudarshan Chemical:
The company announced an offer to acquire 26% of its voting share capitalat an offer price of Rs.578.11 per share.
Wipro Ltd:
The company exceeded expectations with Q2 FY25 net profit up 21% YoY to Rs.3,209 crore, despite a 1% YoY decline in revenue to Rs.22,302 crore.
Zydus Lifesciences:
The company received USFDA approval to manufacture FludrocortisoneAcetate Tablets USP, with the drug's US market valued at USD 19.9 millionannually.
Please refer disclaimer at http://www.aretesecurities.com/
SEBI Regn. No.: INM00001274
Tag News
Indian markets to deliver positive returns for 9th year in a row, outperform US